BIOFARMA
Universitat de Barcelona
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Universitat de Barcelona (29)
2024
-
Exploring Biginelli-based scaffolds as A2B adenosine receptor antagonists: Unveiling novel structure-activity relationship trends, lead compounds, and potent colorectal anticancer agents
Biomedicine and Pharmacotherapy, Vol. 173
-
Stepwise Structural Simplification of the Dihydroxyanthraquinone Moiety of a Multitarget Rhein-Based Anti-Alzheimer Lead to Improve Drug Metabolism and Pharmacokinetic Properties
Pharmaceutics, Vol. 16, Núm. 8
2023
-
A Robust and Efficient FRET-Based Assay for Cannabinoid Receptor Ligands Discovery
Molecules, Vol. 28, Núm. 24
-
Pharmacological insights emerging from the characterization of a large collection of synthetic cannabinoid receptor agonists designer drugs
Biomedicine and Pharmacotherapy, Vol. 164
2022
-
A New Family of Subnanomolar inhibitors of Soluble Epoxide Hydrolase
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, Vol. 36
-
Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease
European Journal of Medicinal Chemistry, Vol. 236
-
Discovery and In Vivo Proof of Concept of a Highly Potent Dual Inhibitor of Soluble Epoxide Hydrolase and Acetylcholinesterase for the Treatment of Alzheimer's Disease
Journal of Medicinal Chemistry, Vol. 65, Núm. 6, pp. 4909-4925
-
Insights into the Pharmacokinetics and In Vitro Cell‐Based Studies of the Imidazoline I2 Receptor Ligand B06
International Journal of Molecular Sciences, Vol. 23, Núm. 10
-
Soluble Epoxide Hydrolase Inhibitors: Design, Synthesis, in vitro Profiling and in vivo Evaluation in Murine Models of Pain
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, Vol. 36
-
Synthesis, In Vitro Profiling, and In Vivo Evaluation of Benzohomoadamantane-Based Ureas for Visceral Pain: A New Indication for Soluble Epoxide Hydrolase Inhibitors
Journal of medicinal chemistry, Vol. 65, Núm. 20, pp. 13660-13680
2021
-
2-(Piperidin-4-yl)acetamides as Potent Inhibitors of Soluble Epoxide Hydrolase with Anti-Inflammatory Activity
Pharmaceuticals, Vol. 14, Núm. 12
-
Benzofuranyl-2-imidazoles as imidazoline I2 receptor ligands for Alzheimer's disease
European Journal of Medicinal Chemistry, Vol. 222
-
From the Design to the in Vivo Evaluation of Benzohomoadamantane-Derived Soluble Epoxide Hydrolase Inhibitors for the Treatment of Acute Pancreatitis
Journal of Medicinal Chemistry, Vol. 64, Núm. 9, pp. 5429-5446
-
From virtual screening hits targeting a cryptic pocket in BACE-1 to a nontoxic brain permeable multitarget anti-Alzheimer lead with disease-modifying and cognition-enhancing effects
European Journal of Medicinal Chemistry, Vol. 225
2020
-
2-Oxaadamant-1-yl Ureas as Soluble Epoxide Hydrolase Inhibitors: In Vivo Evaluation in a Murine Model of Acute Pancreatitis
Journal of medicinal chemistry, Vol. 63, Núm. 17, pp. 9237-9257
-
A novel NMDA receptor antagonist protects against cognitive decline presented by senescent mice
Pharmaceutics, Vol. 12, Núm. 3
-
Bicyclic α-Iminophosphonates as High Affinity Imidazoline I2 Receptor Ligands for Alzheimer's Disease
Journal of Medicinal Chemistry, Vol. 63, Núm. 7, pp. 3610-3633
-
Centrally Active Multitarget Anti-Alzheimer Agents Derived from the Antioxidant Lead CR-6
Journal of Medicinal Chemistry, Vol. 63, Núm. 17, pp. 9360-9390
-
Pharmacological Inhibition of Soluble Epoxide Hydrolase as a New Therapy for Alzheimer’s Disease
Neurotherapeutics, Vol. 17, Núm. 4, pp. 1825-1835
-
Pharmacology and preclinical validation of a novel anticancer compound targeting PEPCK-M
Biomedicine and Pharmacotherapy, Vol. 121